Claseprubart  (Synonyms: DNTH103)

Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Complement C1s

Co-incubation of DNTH103 (0.1 μM, 1 μM) with complement-containing serum from AChR-positive myasthenia gravis patients significantly reduces the muscle contraction fatigue index and improves neuromuscular transmission function in a human iPSC-derived motor neuron-muscle cell co-culture myasthenia gravis model. Its efficacy is superior to that of anti-C5 antibody at the same concentration, and it exerts no significant effect on serum samples from healthy individuals^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

716  [NCBI]

P09871

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.638 kDa

2922766-89-8

Liquid

Colorless to light yellow

[Claseprubart]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG4-kappa

• 
  Loaded Claseprubart on ProA biosensor, can bind HY-P700696 C1s/Complement C1s Protein, Human (HEK293, His) with an affinity constant of 3.648E-09 M as determined in BLI assay.

• [1]. Gokhale S, et al. Classical Pathway Inhibition with Anti-active C1s Antibody DNTH103 Prevents Neurotransmission Impairment in a Preclinical Model of Myasthenia Gravis (S15. 001)[C]//Neurology. Hagerstown, MD: Lippincott Williams & Wilkins, 2024, 102(7_supplement_1): 5614.

  [2]. Katzberg H, et al. Prospects for multi-focal motor neuropathy treatment by complement inhibition[J]. Expert Opinion on Investigational Drugs, 2025, 34(6): 453-457.

  [3]. Ho AWS, et al. Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. EBioMedicine. 2025;122:106009.  [Content Brief]